A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Pfizer

Status and phase: Completed; Phase 4

Conditions: Candidemia; Aspergillosis

Treatments: Drug: anidulafungin and voriconazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00940017

A8851020

Details and patient eligibility

About

The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

Enrollment: 24 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult subjects willing to comply with the study requirement.

Exclusion criteria

• Clinical significant disease.
• Sensitive to study medication.
• Not willing to comply with the study requirement.

Trial design

24 participants in 1 patient group

1

Experimental group

Treatment:

Drug: anidulafungin and voriconazole